MorphoSys AG (Frankfurt: MOR; Prime Standard Segment) today announced the formation of its new business unit “Antibodies by Design”, which will market HuCAL® antibodies in non-therapeutic applications. The range of products and services offered by Antibodies by Design targets primarily industrial and academic institutions requiring custom-generated antibodies for use in research applications. Over one hundred new orders have been acquired to-date thus demonstrating the significant market potential for custom generated research antibodies.
The HuCAL® technology is currently employed at MorphoSys in a number of therapeutic antibody collaborations with renowned pharmaceutical and biotechnology company partners. The Antibodies by Design unit was originally conceived in order to expand the market for MorphoSys’ core competence in the generation of fully human antibodies using its well-established HuCAL® technology. Using the HuCAL® technology, novel research antibodies can be generated within 8 to 10 weeks – a significant speed improvement over the current market standard of 6 to 9 months using animal-based technologies. As part of its core offering, customers of Antibodies by Design are able to send their antigens for processing, and order an appropriate antibody format plus any of a number of other value-adding components.
Leading the new unit is Dieter Lingelbach, who joined MorphoSys in April 2003 from Roche Diagnostics. At Roche Diagnostics he was responsible for global marketing and sales of research and industrial biochemicals. Mr. Lingelbach brings more than 20 years of professional experience in diagnostics sales and marketing, human health care, biotechnology, and management consulting. Ms. Joanne Crowe, previously International Marketing Director responsible for global marketing activities at Qiagen, joined the Antibodies by Design team in May 2003. Ms. Crowe has 8 years of international experience in biological research and more than 12 years of experience in marketing and marketing communications in the life science industry.
“The value chain of MorphoSys, based on the HuCAL® technology, is being expanded by a new link,” comments Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. “I am particularly glad that we have succeeded in hiring two seasoned executives for the new business unit, both of whom have longstanding experience in strategic marketing and international sales of biological products and services.”
“The approach of Antibodies by Design is adding value to the traditional MorphoSys business by penetrating wholly new markets with its innovative technology,” adds Dieter Lingelbach, Manager of Antibodies by Design and Senior Vice President of MorphoSys AG.
The HuCAL® technology is currently employed at MorphoSys in a number of therapeutic antibody collaborations with renowned pharmaceutical and biotechnology company partners. The Antibodies by Design unit was originally conceived in order to expand the market for MorphoSys’ core competence in the generation of fully human antibodies using its well-established HuCAL® technology. Using the HuCAL® technology, novel research antibodies can be generated within 8 to 10 weeks – a significant speed improvement over the current market standard of 6 to 9 months using animal-based technologies. As part of its core offering, customers of Antibodies by Design are able to send their antigens for processing, and order an appropriate antibody format plus any of a number of other value-adding components.
Leading the new unit is Dieter Lingelbach, who joined MorphoSys in April 2003 from Roche Diagnostics. At Roche Diagnostics he was responsible for global marketing and sales of research and industrial biochemicals. Mr. Lingelbach brings more than 20 years of professional experience in diagnostics sales and marketing, human health care, biotechnology, and management consulting. Ms. Joanne Crowe, previously International Marketing Director responsible for global marketing activities at Qiagen, joined the Antibodies by Design team in May 2003. Ms. Crowe has 8 years of international experience in biological research and more than 12 years of experience in marketing and marketing communications in the life science industry.
“The value chain of MorphoSys, based on the HuCAL® technology, is being expanded by a new link,” comments Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. “I am particularly glad that we have succeeded in hiring two seasoned executives for the new business unit, both of whom have longstanding experience in strategic marketing and international sales of biological products and services.”
“The approach of Antibodies by Design is adding value to the traditional MorphoSys business by penetrating wholly new markets with its innovative technology,” adds Dieter Lingelbach, Manager of Antibodies by Design and Senior Vice President of MorphoSys AG.